Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Adedigbo A. Fasanmade(TetraLogic Pharmaceuticals (United States)), Honghui Zhou(Janssen (United States)), Joyce Ford, Chuanpu Hu, Danika Hernandez, Hugh M. Davis(South College), Jewel Johanns(Johnson & Johnson (United States)), Omoniyi J. Adedokun(Western University)
Cited by 322
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2019|1.2k
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
|New England Journal of Medicine|2012|1.1k